| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $3,685,413 ) |
| | 2025 | 2025 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | AY1AX000075 | γδ CAR T-Cellular Vaccine for Solid Cancers | 000 | 1 | NIH | 1/27/2025 | $3,685,413 |
| | 2025 | 2024 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R43CA291415 | An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma | 000 | 1 | NIH | 2/19/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $396,172 ) |
| | 2024 | 2024 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R43CA291415 | An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma | 000 | 1 | NIH | 9/13/2024 | $399,256 |
| | 2024 | 2023 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R44CA278021 | Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies | 000 | 1 | NIH | 1/29/2024 | $0 |
| | 2024 | 2023 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R43AI179375 | Allogeneic BAFF Ligand Based CAR T-Cells as a Novel Therapy for Systemic Lupus Erythematous | 000 | 1 | NIH | 8/28/2024 | $0 |
| | 2024 | 2021 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R43CA254820 | Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy | 000 | 1 | NIH | 3/6/2024 | -$3,084 |
|
| Issue Date FY: 2023 ( Subtotal = $696,991 ) |
| | 2023 | 2023 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R43AI179375 | Allogeneic BAFF Ligand Based CAR T-Cells as a Novel Therapy for Systemic Lupus Erythematous | 000 | 1 | NIH | 8/1/2023 | $299,770 |
| | 2023 | 2023 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R44CA278021 | Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies | 000 | 1 | NIH | 6/30/2023 | $397,934 |
| | 2023 | 2020 | LUMINARY THERAPEUTICS, INC. | 1200 WASHINGTON AVE S STE 260 | MINNEAPOLIS | MN | 55415-7540 | HENNEPIN | USA | R43CA254794 | MyD88 fusion protein with antigen specific T Cell therapy for enhanced response in solid tumors | 000 | 1 | NIH | 10/17/2022 | -$713 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | LUMINARY THERAPEUTICS, INC. | 1621 E HENNEPIN AVE STE 290 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R43CA254794 | MyD88 fusion protein with antigen specific T Cell therapy for enhanced response in solid tumors | 000 | 1 | NIH | 1/31/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $399,658 ) |
| | 2021 | 2021 | LUMINARY THERAPEUTICS, INC. | 1621 E HENNEPIN AVE STE 290 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R43CA254820 | Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy | 000 | 1 | NIH | 7/19/2021 | $399,658 |
|
| Issue Date FY: 2020 ( Subtotal = $397,422 ) |
| | 2020 | 2020 | LUMINARY THERAPEUTICS, INC. | 1621 E HENNEPIN AVE STE 290 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R43CA254794 | MyD88 fusion protein with antigen specific T Cell therapy for enhanced response in solid tumors | 000 | 1 | NIH | 9/8/2020 | $397,422 |
|
|
